Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vir Biotechnology, Inc. Director's Dealing 2021

Dec 3, 2021

32538_dirs_2021-12-03_1d9f59b4-b678-4e07-b784-5bc367e2c50b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2021-12-01

Reporting Person: Pang Phillip (Chief Medical Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-12-01 Common Stock S 950 $41.82 Disposed 99327 Direct
2021-12-01 Common Stock S 4409 $43.46 Disposed 94918 Direct
2021-12-01 Common Stock S 2050 $44.10 Disposed 92868 Direct
2021-12-01 Common Stock S 91 $44.97 Disposed 92777 Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.41 to $42.31 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.83 to $43.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.84 to $44.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.